Testosterone therapy and cardiovascular risk

Trends in Cardiovascular Medicine

Volumn 25, Issue 3, 2015, Pages 250-257

  Walsh, James P ^a,b   Kitchens, Anne C ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN THERAPY; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG MECHANISM; HUMAN; MALE; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL; VASCULARIZATION; ADULT; ADVERSE EFFECTS; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; HORMONE SUBSTITUTION; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; TESTOSTERONE;

EID: 84925218589     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.10.014     Document Type: Review

References (49)

1. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001, 86:724-731.
2. Braun S.A. Promoting "low-T", a medical writer[U+05F3]s perspective. J Am Med Assoc Int Med 2013, 173:1458-1460.
3. Baillargeon J., Urban R.J., Otenbacher K.J., Pierson K.S., Goodwin J.S. Trends in androgen prescribing in the United States, 2001 to 2011. J Am Med Assoc Int Med 2013, 173:1465-1466.
4. Layton J.B., Li D., Meier C.R., Sharpless J.L., Sturmer T., Jick S.S., et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 2014, 99:835-842.
5. Pope H.G., Wood R.I., Rogol A., Nyberg F., Bowers L., Bhasin S. Adverse health consequences of performance enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014, 35:341-375.
6. Ruige J.B., Mahmoud A.M., De Bacquer D., Kaufman J.M. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011, 97:870-875.
7. Vigen R., O'Donnell C.I., Baron A.E., Grunwald G.K., Maddox T.M., Bradley S.M., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. J Am Med Assoc 2013, 310:1829-1836.
8. Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014, 9:e85805.
9. Reyes-Fuentes A., Veldhuis J.D. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol Metab Clin North Am 1993, 22:93-124.
10. Mooradian A.D., Morley J.E., Korenman S.G. Biological actions of androgens. Endocr Rev 1987, 8:1-28.
11. Rahman F., Christian H.C. Non-classical actions of testosterone: an update. Trends Endocrinol Metab 2007, 18:371-378.
12. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
13. Ruige J.B., Ouwens M., Kaufman J.M. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab 2013, 98:4300-4310.
14. Herring M.J., Oskui P.M., Hale S.L., Kloner R.A. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc 2013, 2:e000271.
15. Chambliss K.L., Shaul P.W. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002, 23:665-686.
16. Deenadayalu V., Puttabyatappa Y., Liu A.T., Stallone J.N., White R.E. Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol 2012, 302:H115-H123.
17. Eyster K.M., Mark C.J., Gayle R., Martin D.S. The effects of estrogen and testosterone on gene expression in rat mesenteric arteries. Vasc Pharmacol 2007, 47:238-247.
18. Travison T.G., Araujo A.B., Kupelian V., O[U+05F3]Donnell A.B., McKinlay J.B. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007, 92:549-555.
19. Grossman M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011, 96:2341-2353.
20. Kalyani R.R., Gavini S., Dobs A.S. Male hypogonadism in chronic disease. Endocrinol Metab Clin North Am 2007, 36:333-348.
21. Araujo A.B., Dixon J.M., Suarez E.A., Murad M.H., Guey L.T., Wittert G.A. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011, 96:3007-3019.
22. Corona G., Rastrelli G., Monami M., Guay A., Buvat J., Sforza A., et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011, 165:687-701.
23. Jankowska E.A., Biel B., Majda J., Szklarska A., Lopuszanska M., Medras M., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006, 114:1829-1837.
24. Basaria S. Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale. Endocr Pract 2013, 19:853-863.
25. Levine G.N., D[U+05F3]Amico A.V., Berger P., Clark P.E., Eckel R.H., Keating N.L., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
26. Nguyen P.L., Je Y., Schutz F.A.B., Hoffman K.E., Hu J.C., Parekh A., et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer. J Am Med Assoc 2011, 306:2359-2366.
27. Shores M.M., Smith N.L., Forsberg C.W., Anawalt B.D., Matsumoto A.M. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012, 97:2050-2058.
28. Muraleedharan V., Marsh H., Kapoor D., Channer K.S., Jones T.H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013, 169:725-733.
29. Basaria S., Coviello A.D., Travison T.G., Storer T.W., Farwell W.R., Jette A.M., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
30. Basaria S., Davda M.N., Travison T.G., Ulloor J., Singh R., Bhasin S. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2013, 68:153-160.
31. Xu L., Freeman G., Cowling B.J., Schooling C.M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo controlled randomized trials. BMC Med 2013, 11:108.
32. Corona G., Maseroli E., Rastrelli G., Isidori A.M., Sforza A., Mannucci E., et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014, 13:1327-1351.
33. Haddad R.M., Kennedy C.C., Caples S.M., Tracz M.J., Bolona E.R., Sideras K., et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:29-39.
34. Frenandez-Balsells M.M., Murad M.H., Lane M., Lampropulos J.F., Albuquerque F., Mullan R.J., et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:2560-2575.
35. Jones T.H. Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes 2010, 2:146-156.
36. Toma M., McAlister F.A., Coglianese E.E., Vidi V., Vasaiwala S., Bakal J.A., et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012, 5:315.
37. English K.M., Steeds R.P., Jones T.H., Diver M.J., Channer K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000, 102:1906-1911.
38. Malkin C.J., Pugh P.J., Morris P.D., Kerry K.E., Jones R.D., Jones T.H., et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004, 90:871-876.
39. Mathur A., Malkin C., Saeed B., Muthusamy R., Jones T.H., Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009, 161:443-449.
40. Brown D.W., Giles W.H., Croft J.B. Hematocrit and the risk of coronary heart disease mortality. Am Heart J 2001, 142:657-663.
41. Glueck C.J., Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism 2014, 63:989-994.
42. Wu O., Robertson L., Langhorne P., Twaddle S., Lowe G.D.O., Clark P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. Thromb Haemost 2005, 94:17-25.
43. Olie V., Canonico M., Scarabin P.Y. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010, 17:457-463.
44. Mannucci P.M., Asselta R., Duga S., Guella I., Spreafico M., Lotta L., et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. Thromb Haemost 2010, 8:2116-2121.
45. Endocrine Society. The risk of cardiovascular events in men receiving testosterone therapy. ; 2014 [accessed 30.8.14]. http://www.endocrine.org/advocacy-and-outreach/position-statements/other-society-statements.
46. U.S. Food and Drug Administration. Testosterone products: FDA/CDER statement-risk of venous blood clots. ; 2014 [accessed 30.8.14]. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm.
47. Von Drehle D. Manopause!? Aging, insecurity and the $2 billion testosterone industry. Time, U.S. ed. 2014 184:36-43.
48. Wang C., Nieschlag E., Swerdloff R., Behre H.M., Hellstrom W.J., Gooren L.J., et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. J Androl 2009, 30:1-9.
49. Basaria S. Need for standardizing adverse event reporting in testosterone trials. Evid Based Med 2014, 19:32-33.